Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-08-15
2006-08-15
Chernyshev, Olga N. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S007900, C435S007920, C435S006120, C435S007800, C514S002600
Reexamination Certificate
active
07090982
ABSTRACT:
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patients with peptides are provided. Multiple sclerosis patients can be screened for the presence of an human leukocyte antigen (HLA)-DR2 haplotype. The presence of the human leukocyte antigen (HLA)-DR2 haplotype in a patient is predictive of therapeutic efficacy of treatment.
REFERENCES:
patent: 6379670 (2002-04-01), Gaur et al.
patent: WO 80/02501 (1980-11-01), None
patent: WO 88/00057 (1988-01-01), None
patent: WO 95/31990 (1995-11-01), None
patent: WO 96/16085 (1996-05-01), None
patent: WO 96/28470 (1996-09-01), None
Hauser et al., 1989, Neurology, 39, pp. 275-277.
Salvetti et al., 1993, Eur. J. Immunology, 23, pp. 1232-1239.
Catz Ingrid
Warren Kenneth G.
Chernyshev Olga N.
Pillsbury Winth Winthrop Shaw Pittman LLP
The Governors of The University of Alberta
LandOfFree
Methods of predicting therapeutic efficacy of treatment of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of predicting therapeutic efficacy of treatment of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of predicting therapeutic efficacy of treatment of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3632256